

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE (Cardboard box)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zodon 150 mg chewable tablets

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains:

Clindamycin (as hydrochloride) .....150 mg

**3. PACKAGE SIZE**

8 tablets  
16 tablets  
96 tablets  
240 tablets

**4. TARGET SPECIES**

Dogs

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp {mm/yyyy}

Once opened use within 72 hours.

**9. SPECIAL STORAGE PRECAUTIONS**

Do not store above 30°C.

Tablet portions should be stored in the blister pack. Keep the blister in the outer carton.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Ceva Sante Animale

**14. MARKETING AUTHORISATION NUMBERS**

Vm 14966/5095

Vm 14966/3095

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING  
UNITS (BLISTERS)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zodon



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

150 mg of clindamycin (as hydrochloride)

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

**PACKAGE LEAFLET**

**1. Name of the veterinary medicinal product**

Zodon 150 mg chewable tablets for dogs

**2. Composition**

Each tablet contains

**Active substance:**

Clindamycin (as hydrochloride) .....150 mg

Clover-shaped scored beige tablet. The tablet can be divided into four equal parts.

**3. Target species**

Dogs

**4. Indications for use**

- For the treatment of infected wounds and abscesses, and oral cavity infections including periodontal disease, caused by or associated with *Staphylococcus* spp., *Streptococcus* spp. (except *Streptococcus faecalis*), *Bacteroides* spp., *Fusobacterium necrophorum*, and *Clostridium perfringens*.
- For the treatment of superficial pyoderma associated with *Staphylococcus pseudintermedius*.
- For the treatment of osteomyelitis, caused by *Staphylococcus aureus*.

**5. Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients or to lincomycin

Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants. because ingestion of clindamycin by these species may result in severe gastrointestinal disturbance.

**6. Special warnings**

Special warnings

None

Special precautions for safe use in the target species

The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal.

Official and local antimicrobial policies should be taken into account when the product is used.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to clindamycin and may decrease the effectiveness of treatment with lincomycin or macrolide antimicrobials due to the potential for cross-resistance

Clindamycin and erythromycin show parallel resistance. Partial cross-resistance has been demonstrated between clindamycin, erythromycin and other macrolide antibiotics.

During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

Animals with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high-dose clindamycin therapy.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to lincosamides (lincomycin and clindamycin) should avoid contact with the veterinary medicinal product.

Wash hands after handling tablets.

Accidental ingestion may result in gastro-intestinal effects such as abdominal pain and diarrhoea. Care should be taken to avoid accidental ingestion.

In case of accidental ingestion, particularly by children, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

No applicable

Pregnancy and lactation:

While high dose studies in rats suggest that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety in gestating bitches or breeding male dogs has not been established.

Clindamycin crosses the placental and the blood-milk barrier.

Treatment of lactating females can cause diarrhoea in puppies.

Use the product only according to the benefit/risk assessment by the responsible veterinarian.

The use of the product is not recommended in neonates.

Interaction with other medicinal products and other forms of interaction:

Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.

The product should be used with caution in animals receiving such agents.

Clindamycin should not be combined with erythromycin or other macrolides to prevent macrolide-induced resistance to clindamycin.

Clindamycin may reduce plasma levels of cyclosporin with a risk of lack of activity.

During the simultaneous use of clindamycin and aminoglycosides (eg gentamicin), the risk of adverse interactions (acute renal failure) cannot be excluded.

Overdose:

In dogs, oral doses of clindamycin up to 300 mg/kg/day did not result in toxicity.

Dogs receiving 600 mg/kg/day of clindamycin developed anorexia, vomiting and weight loss. In cases of overdose, discontinue treatment immediately and

establish symptomatic treatment.

## 7. Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction Thrombocytopenia Vomiting, diarrhoea
---	--

Clindamycin sometimes causes the overgrowth of non-sensitive organisms such as clostridia and yeasts. In cases of superinfection, appropriate measures must be taken according to the clinical situation.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## 8. Dosage for each species, routes

Oral use.

- For the treatment of infected wounds and abscesses, and oral cavity infections including periodontal disease, administer either:
  - 5.5 mg/kg of bodyweight every 12 hours for 7-10 days, or
  - 11 mg/kg of bodyweight every 24 hours for 7-10 days

If no clinical response is seen within 4 days, redetermine the diagnosis.

- For the treatment of superficial pyoderma in dogs, administer either:
  - 5.5 mg/kg of bodyweight every 12 hours, or
  - 11 mg/kg of bodyweight every 24 hours

Therapy of superficial pyoderma is usually recommended for 21 days, with extension of therapy based on clinical judgement.

- For the treatment of osteomyelitis in dogs, administer:
  - 11 mg/kg of bodyweight every 12 hours for a minimum of 28 days

If no clinical response is seen within 14 days, the treatment should be stopped and the diagnosis redetermined.

For example:

- For a dose regimen of 11mg/kg

Weight (kg)	Number of tablets per administration
2.5 – 3.4	¼ tab
3.4- 4.4	Use Zodon 88 mg
4.5 – 6.5	½ tabs
6.6– 10.0	¾ tab
10.1 – 13.5	1 tab
13.6 – 17.0	1 + ¼ tabs
17.1 – 20.5	1 + ½ tabs
20.6 – 23.9	1 + ¾ tabs
24.0 – 27.0	2 tabs

- For a dose regimen of 5.5 mg/kg

Weight (kg)	Number of tablets per administration
2.5- 4.4	Use Zodon 88 mg
4.5 – 6.5	¼ tab
6.6– 13.5	½ tab
13.6 – 20.5	¾ tab
20.6 – 27.0	1 tab

To ensure a correct dosage, body weight should be determined as accurately as possible.

## 9. Advice on correct administration

The tablets are flavoured. They can be administered directly into the mouth of the animals or with a small quantity of food.

Instruction on how to divide the tablet: Put the tablet on an even surface, with its scored side facing down (convex face up). With the tip of the forefinger, exert slight vertical pressure on the middle of the tablet to break it along its width into halves. Then, in order to obtain quarters, exert slight pressure on the middle of one half with the forefinger to break it into two parts.

## 10. Withdrawal periods

Not applicable

## 11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 30°C.

Tablet portions should be stored in the blister pack.  
Shelf life for tablet portions after first opening the immediate packaging: 72 hours (or 3 days)  
Keep the blister in the outer carton.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister after {Exp}. The expiry date refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 14966/5095

Vm 14966/3095

### Pack sizes:

Cardboard box with 8 tablets

Cardboard box with 16 tablets

Cardboard box with 96 tablets

Cardboard box with 240 tablets

Not all pack sizes may be marketed.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## **15. Contact details**

### Marketing Authorisation Holder:

Ceva Sante Animale

8 rue de Logrono

33500 Libourne

France

Contact details to report suspected adverse reactions:

Ceva Animal Health Ltd  
Explorer House, Mercury Park  
Wycombe Lane, Wooburn Green  
High Wycombe  
Buckinghamshire  
HP10 0HH  
United Kingdom  
Tel: 00800 35 22 11 51  
Email for the reporting of adverse events: [pharmacovigilance@ceva.com](mailto:pharmacovigilance@ceva.com)

Manufacturer responsible for batch release:

Ceva Santé Animale  
Boulevard de la Communication  
Zone Autoroutière  
53950 LOUVERNE  
FRANCE

**16. Other information**

POM-V

For animal treatment only

*Gavin Hall*  
Approved: 02 December 2025